[Potentiation of nitric oxide-dependent activation of soluble guanylate cyclase by levomycetin, tetracycline, and oxolin].
The influence of antibiotics laevomycetin and tetracycline and the antivirus agent oxolin on the activity of human platelet soluble guanylate cyclase, the stimulation of the enzyme by NO-donors (sodium nitroprusside (SNP) and spermine nanoate (spermine NONO)) and the combination of spermine NONO and YC-1 was investigated. All preparations used in the concentration range 0,1-10 mM had no effect on the basal activity of guanylate cyclase but potentiated the SNP-induced activation of this enzyme. All preparations used synergistically increased (similar to YC-1) spermine NONO-induced activation of soluble guanylate cyclase. At the same time these compounds did not produce the leftward shift of spermine NONO concentration response curve characteristic for YC-1. Moreover, all compounds used did not influence the leftward shift of spermine NONO concentration response curve obtained in the presence of YC-1. This demonstrated that there was no competition between YC-1 and the drugs for interaction with the enzyme. The revealed regulatory phenomen of laevomycetin, tetracycline and oxolin to increase synergistically NO-dependent activation of soluble guanylate cyclase may cause additional pharmacological effects during prolong treatment by these drugs. This fact is necessary taking into account.
Shchegolev
A Iu
AIu
Sidorova
T A
TA
Severina
I S
IS
D000900:Anti-Bacterial Agents / Q000494:pharmacology; D000998:Antiviral Agents / Q000494:pharmacology; D001792:Blood Platelets / Q000187:drug effects* / Q000378:metabolism; D002701:Chloramphenicol / Q000494:pharmacology*; D004357:Drug Synergism; D004789:Enzyme Activation / Q000187:drug effects; D006162:Guanylate Cyclase / Q000037:antagonists & inhibitors / Q000378:metabolism*; D006801:Humans; D066298:In Vitro Techniques; D007191:Indazoles / Q000494:pharmacology; D009569:Nitric Oxide / Q000502:physiology*; D020030:Nitric Oxide Donors / Q000494:pharmacology; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D018160:Receptors, Cytoplasmic and Nuclear / Q000819:agonists / Q000037:antagonists & inhibitors / Q000378:metabolism*; D000071756:Soluble Guanylyl Cyclase; D013752:Tetracycline / Q000494:pharmacology*; D013764:Tetrahydronaphthalenes / Q000494:pharmacology*
D000900:Anti-Bacterial Agents; D000998:Antiviral Agents; D007191:Indazoles; D020030:Nitric Oxide Donors; D010975:Platelet Aggregation Inhibitors; D018160:Receptors, Cytoplasmic and Nuclear; D013764:Tetrahydronaphthalenes; C090937:3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole; C003020:oxoline; D009569:Nitric Oxide; D002701:Chloramphenicol; D006162:Guanylate Cyclase; D000071756:Soluble Guanylyl Cyclase; D013752:Tetracycline